Genmab A/S has grown revenue 37% a year over three years and 32% a year over five, with earnings per share compounding at 39%. Revenue growth, 3-year annual rate: +37% (Biotechnology median +17%). Revenue growth, 5-year rate: +32%, growth has picked up over the last three years. Earnings per share, 3-year rate: +39%, earnings outgrew revenue: margins or the share count worked for shareholders. Years of annual history on file: 9, FY2017 to FY2025, as filed.

GMABGenmab A/S

Healthcare

$37.06+31% 1Y

$37.06

$23.8552 weeks$38.47

Is it growing?

Watch

Operating margin narrowing (−7.0 points). That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.

1 to watch, 2 without data

Margin direction−7.0 points operatingSEC EDGAR · Jun 30, 2024

Trailing-twelve-month operating margin, 24.8% now against 31.8% a year earlier.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is GMAB growing?

Genmab A/S has grown revenue 37% a year over three years and 32% a year over five, with earnings per share compounding at 39%.

+37%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from fiscal-year columns as filed

Revenue growth, 5-year rate: +32%
Revenue growth, 5-year rate · +37% over three · growth has picked up over the last three years
Earnings per share, 3-year rate: +39%
Earnings per share, 3-year rate · revenue +37% · earnings outgrew revenue: margins or the share count worked for shareholders
Years of annual history on file: 9
Years of annual history on file · FY2017 to FY2025, as filed